<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626413</url>
  </required_header>
  <id_info>
    <org_study_id>Silesia diabetes - heart</org_study_id>
    <nct_id>NCT05626413</nct_id>
  </id_info>
  <brief_title>Cardiovascular Disease in Patients With Diabetes: The Silesia Diabetes-Heart Project</brief_title>
  <official_title>Cardiovascular Disease and Diabetes in Silesian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Silesian University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is an observational one which undertakes different, easy to obtain in everyday&#xD;
      clinical practice, demographical, laboratory and clinical parameters of patients with&#xD;
      diabetes in Silesian Region in Poland to predict cardiovascular disease and cardiovascular&#xD;
      events using machine learning approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, observational one in which it is planned to obtain demographical,&#xD;
      laboratory and clinical parameters of patients who are hospitalized in one the the main&#xD;
      diabetology sites in Silesia region in Poland and to follow them prospectively for 10 years&#xD;
      in order to collect information related to new cardiovascular events. Telephone contact will&#xD;
      be performed every 12 months following hospital discharge. Any procedures related to the&#xD;
      patients hospitalized in the diabetology ward will be the routine ones and the bioethics&#xD;
      committee of Medical University of Silesia gave the permission for the study but waved the&#xD;
      necessity of informed consent to be signed.Moreover there will be subgroup analysis of&#xD;
      patients recruited from the outpatient diabetology clinics in Silesia region in order to&#xD;
      participate in the observational study collecting data related to to vitamin D concentration,&#xD;
      densitometry, fibroscan, carotid ultrasound examination, vascular stiffness, and peripheral&#xD;
      and cardiovascular neuropathy. Patients who are treated in outpatient diabetology clinics in&#xD;
      Silesia region and are included into the study must have the informed consent signed and&#xD;
      bioethics committee agreement has been obtained. Machine learning approach will be&#xD;
      implemented to discover the association between easy to obtain in everyday practice&#xD;
      parameters, namely clinical, biochemical, and demographical ones to identify patients at the&#xD;
      highest risk of cardiovascular disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>The risk of cardiovascular disease and events among patients with diabetes</measure>
    <time_frame>5 years</time_frame>
    <description>To predict the risk of cardiovascular disease and events among patients with diabetes using machine learning approach</description>
  </primary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized in diabetology ward in Zabrze. Patients treated in outpatient&#xD;
        diabetology clinics in Silesia region.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For the group of hospitalized patients: diabetes type 1 or type 2&#xD;
&#xD;
          -  For the subgroup of patients treated in outpatient diabetology clinics in Silesia&#xD;
             region: diabetes type 1 or type 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For the group of hospitalized patients:&#xD;
&#xD;
               -  Types of diabetes other than type 1 and type 2 diabetes&#xD;
&#xD;
               -  Death during hospital stay&#xD;
&#xD;
               -  Terminal stage of cancer.&#xD;
&#xD;
          2. For the subgroup of patients recruited form outpatient diabetology clinics:&#xD;
&#xD;
               -  Lack of an informed consent&#xD;
&#xD;
               -  Types of diabetes other than type 1 and type 2 diabetes&#xD;
&#xD;
               -  Malignant neoplasms&#xD;
&#xD;
               -  Terminal stage of neoplasm&#xD;
&#xD;
               -  End-stage renal disease&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
               -  Primary hyperparathyroidism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarzyna Nabrdalik, PhD,prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Silesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna Nabrdalik, PhD, prof.</last_name>
    <phone>0048697592954</phone>
    <email>knabrdalik@sum.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanna Kwiendacz, PhD</last_name>
    <phone>0048509774849</phone>
    <email>hkwiendacz@sum.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Diseases, Diabetology and Nephrology</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Kwiendacz, MD,PhD</last_name>
      <phone>0048509774849</phone>
      <email>hkwiendacz@sum.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Katarzyna Nabrdalik, MD,PhD,prof</last_name>
      <phone>0048697592954</phone>
      <email>knabrdalik@sum.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Katarzyna Nabrdalik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janusz Gumprecht, MD,PhD,Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Kwiendacz, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karolina Drożdż, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakub Nalepa, PhD, prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>December 2, 2022</last_update_submitted>
  <last_update_submitted_qc>December 2, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

